Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future

References

• International Diabetes Federation. IDF Atlas Ninth Edition (full). 2019. Available at URL: https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf.
   Google Scholar
• Liu J, Ren Z-H, Qiang H, et al. Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 2020;20(1):1415.
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Ogle GD, Lund-Blix NA, et al. Update on worldwide trends in occurrence of childhood type 1 diabetes in 2020. Pediatr Endocrinol Rev. 2020;17(Suppl 1):198–209.
   PubMed Web of Science ®Google Scholar
• Patterson CC, Karuranga S, Salpea P, et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107842.
   PubMed Web of Science ®Google Scholar
• Godman B, Basu D, Pillay Y, et al. Ongoing and planned activities to improve the management of patients with type 1 diabetes across Africa; implications for the future. Hosp Pract. 2020;48(2):51–67.
   PubMedGoogle Scholar
• Godman B, Basu D, Pillay Y, et al. Review of ongoing activities and challenges to improve the care of patients with type 2 diabetes across africa and the implications for the future. Front Pharmacol. 2020; 11:108.
   PubMed Web of Science ®Google Scholar
• Ceriello A, deValk HW, Guerci B, et al. The burden of type 2 diabetes in Europe: current and future aspects of insulin treatment from patient and healthcare spending perspectives. Diabetes Res Clin Pract. 2020;161:108053.
   PubMed Web of Science ®Google Scholar
• Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet. 2021;396(10267):2019–2082.
   PubMed Web of Science ®Google Scholar
• Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41(5):963–970.
   PubMed Web of Science ®Google Scholar
• Mapa-Tassou C, Katte JC, Mba Maadjhou C, et al. Economic impact of diabetes in Africa. Curr Diab Rep. 2019;19(2):5.
   PubMed Web of Science ®Google Scholar
• Tusa BS, Weldesenbet AB, Gemada AT, et al. Heath related quality of life and associated factors among diabetes patients in sub-Saharan countries: a systemic review and meta-analysis. Health Qual Life Outcomes. 2021;19(1):31.
   PubMed Web of Science ®Google Scholar
• Rwegerera GM, Moshomo T, Gaenamong M, et al. Health-related quality of life and associated factors among patients with diabetes mellitus in Botswana. Alexandria J Med. 2018;54(2):111–118.
   Web of Science ®Google Scholar
• Iqbal Q, Ul Haq N, Bashir S, et al. Profile and predictors of health related quality of life among type II diabetes mellitus patients in Quetta city, Pakistan. Health Qual Life Outcomes. 2017;15(1):142.
   PubMed Web of Science ®Google Scholar
• Urakami T, Kuwabara R, Yoshida K. Economic impact of diabetes in Japan. Curr Diab Rep. 2019;19(1):2.
   PubMed Web of Science ®Google Scholar
• Li S, Wang J, Zhang B, et al. Diabetes mellitus and cause-specific mortality: a population-based study. Diabetes Metab J. 2019;43(3):319–341.
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Jakab M, Gerdtham U, et al. Comparative financing analysis and political economy of noncommunicable diseases. J Med Econ. 2019;22(8):722–727.
   PubMed Web of Science ®Google Scholar
• Biorac N, Jakovljević M, Stefanović D, et al. [Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia]. Vojnosanit Pregl. 2009;66(4):271–276.
   PubMed Web of Science ®Google Scholar
• Gerstein HC. Diabetes: dysglycaemia as a cause of cardiovascular outcomes. Nat Rev Endocrinol. 2015;11(9):508–510.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Matter-Walstra K, Sugahara T, et al. Cost-effectiveness and resource allocation (CERA) 18 years of evolution: maturity of adulthood and promise beyond tomorrow. Cost Eff Resour Alloc. 2020;18:15.
   PubMed Web of Science ®Google Scholar
• Nakamura J, Kamiya H, Haneda M, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig. 2017;8(3):397–410.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard U, Alsifri S, Aronson R, et al. Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies. Diabetes Obes Metab. 2019;21(4):844–853.
   PubMed Web of Science ®Google Scholar
• Brod M, Wolden M, Christensen T, et al. Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization. Value Health. 2013;16(8):1140–1149.
   PubMed Web of Science ®Google Scholar
• Baruah MP, Kalra S, Bose S, et al. An Audit of Insulin Usage and Insulin Injection Practices in a Large Indian Cohort. Indian J Endocr Metab. 2017;21(3):443–452.
   PubMedGoogle Scholar
• Venkataraman AP, Laxminarayana K, Knowledge SS. Attitude and Practice of Insulin Use of Diabetic Patients in India. Pharmacol Clin Pharm Res. 2020;5(1):23–32.
   Google Scholar
• Elliot J, Besançon S, Sachs J. Almost 100 years after it was discovered, let’s make access to insulin a reality in Africa! 2016. Available at URL: https://ideas4development.org/en/almost-100-years-after-it-was-discovered-lets-make-access-to-insulin-a-reality-in-africa/.
   Google Scholar
• Rys P, Wojciechowski P, Rogoz-Sitek A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. 2015;52(4):649–662.
   PubMed Web of Science ®Google Scholar
• Dżygało K, Golicki D, Kowalska A, et al. The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials. Acta Diabetol. 2015;52(2):231–238.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014;2(7):553–561.
   PubMed Web of Science ®Google Scholar
• Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;11:CD005613.
   PubMed Web of Science ®Google Scholar
• Khunti K, HAT Investigator Group, Alsifri S, Aronson R, Cigrovski Berković M, Enters-Weijnen C, Forsén T, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907–915.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Ashoor HM, Antony J, et al. Comparative efficacy and safety of ultra-long-acting, long-acting, intermediate-acting, and biosimilar insulins for type 1 diabetes mellitus: a systematic review and network meta-analysis. J Gen Intern Med. 2021. DOI:10.1007/s11606-021-06642-7
   PubMed Web of Science ®Google Scholar
• Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diab Endocrinol. 2017;5(5):355–366.
   PubMed Web of Science ®Google Scholar
• Pathan MF, Fariduddin M, Nazimuddin K, Mollah AS, et al. The incidence of hypoglycemia among insulin-treated patients with type 1 or type 2 diabetes: Bangladeshi Cohort of International Operations-Hypoglycemia Assessment Tool Study. Indian J Endocrinol Metab. 2018;22(3):379–386.
   PubMedGoogle Scholar
• Hussein Z, HAT study investigators in Malaysia, Kamaruddin NA, Chan SP, Jain A, Uppal S, Bebakar WMW. Hypoglycemia awareness among insulin-treated patients with diabetes in Malaysia: A cohort subanalysis of the HAT study. Diabetes Res Clin Pract. 2017;133:40–49.
   PubMed Web of Science ®Google Scholar
• Ewen M, Joosse HJ, Beran D, et al. Insulin prices, availability and affordability in 13 low-income and middle-income countries. BMJ Glob Health. 2019;4(3):e001410.
   PubMed Web of Science ®Google Scholar
• Zion Market Research. Insulin Glargine Market: by Type (Pre-filled Syringe and Single Dose Vial), by Application (Type 1 Diabetes and Type 2 Diabetes), by Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy and Other Distribution Channels): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2025 2019. Available at URL: https://www.zionmarketresearch.com/report/insulin-glargin-market.
   Google Scholar
• PMLive. Levemir. Available at URL: http://www.pmlive.com/top_pharma_list/pharmaceutical_products/levemir.
   Google Scholar
• PharmaLive. NOVO NORDISK 2018. STRUGGLING AGAINST THE TIDE. 2018. Available at URL: https://www.pharmalive.com/novo-nordisk-2018-struggling-against-the-tide/.
   Google Scholar
• Permsuwan U, Thavorn K, Dilokthornsakul P, et al. Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective. J Med Econ. 2017;20(9):991–999.
   PubMed Web of Science ®Google Scholar
• Shafie AA, Ng CH. Cost-effectiveness of insulin glargine and insulin detemir in the basal regimen for naïve insulin patients with type 2 diabetes mellitus (T2DM) in Malaysia. Clinicoecon Outcomes Res. 2020;12:333–343.
   PubMed Web of Science ®Google Scholar
• Mezquita-Raya P, Darbà J, Ascanio M, et al. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):587–595.
   PubMed Web of Science ®Google Scholar
• Evans M, Moes RGJ, Pedersen KS, et al. Cost-effectiveness of insulin degludec versus insulin glargine u300 in the netherlands: evidence from a randomised controlled trial. Adv Ther. 2020;37(5):2413–2426.
   PubMed Web of Science ®Google Scholar
• Su W, Li C, Zhang L, et al. Meta-analysis and cost-effectiveness analysisof insulin glargine 100 u/ml versus insulin degludec for the treatment of type 2 diabetes in China. Diabetes Ther. 2019;10(5):1969–1984.
   PubMed Web of Science ®Google Scholar
• Caires de Souza AL, de Assis Acurcio F, Guerra Junior AA, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12(1):19–32.
   PubMedGoogle Scholar
• Opanga S, Njeri LW, Kimonge D, et al. Assessing utilisation and expenditure on long-acting insulin analogues in kenya; findings and implications for the future. Sch Acad J Pharm. 2021; 10(4):63–70.
   Google Scholar
• Chow CK, Ramasundarahettige C, Hu W, PURE investigators, et al. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabetes Endocrinol. 2018;6(10):798–808.
   PubMed Web of Science ®Google Scholar
• Saeed A, Saeed H, Saleem Z, et al. Impact of National Drug Pricing Policy 2018 on access to medicines in Lahore division, Pakistan: a pre-post survey study using WHO/HAI methodology. BMJ Open. 2020;10(10):e034720.
   PubMed Web of Science ®Google Scholar
• Datta BK, Husain MJ, Fatehin S. The crowding out effect of out-of-pocket medication expenses of two major non-communicable diseases in Pakistan. Int Health. 2020;12(1):50–59.
   PubMed Web of Science ®Google Scholar
• Gillani AH, Aziz MM, Masood I, Saqib A, et al. Direct and indirect cost of diabetes care among patients with type 2 diabetes in private clinics: a multicenter study in Punjab, Pakistan. Expert Rev Pharmacoeconomics Outcomes Res. 2018;18(6):647–653.
   PubMed Web of Science ®Google Scholar
• Ahmad NS, Islahudin F. Affordability of essential medicine prices in Malaysia's private health sector. PPA. 2018;12:1231–1237.
   Web of Science ®Google Scholar
• Puteh SEW, Ahmad SNA, Aizuddin AN, et al. Patients' willingness to pay for their drugs in primary care clinics in an urbanized setting in Malaysia: a guide on drug charges implementation. Asia Pac Fam Med. 2017;16:5.
   PubMedGoogle Scholar
• You HW, Tajuddin NSA, Anwar YAS. Measuring availability, prices and affordability of ischaemic heart disease medicines in Bangi, Selangor, Malaysia. Malays J Med Sci. 2019;26(5):113–121.
   PubMed Web of Science ®Google Scholar
• World Health Organization - Model List of Essential Medicines. 21st List 2019. Available at URL: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1.
   Google Scholar
• Almeida P, Silva TBC, de Assis Acurcio F, et al. Quality of life of patients with type 1 diabetes mellitus using insulin analog glargine compared with NPH insulin: a systematic review and policy implications. Patient. 2018;11(4):377–389.
   PubMedGoogle Scholar
• Department of Health Republic of South Africa. National Essential Medicines List Committee (NEMLC) - TERTIARY AND QUATERNARY LEVEL ESSENTIAL MEDICINES LIST Reviewed Items. 2020. Available at URL: http://www.kznhealth.gov.za/pharmacy/Tertiary-quaternary-level-essential-medicine-recommendations_January2020.pdf.
   Google Scholar
• Lee TY, Kuo S, Yang CY, et al. Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years. Br J Clin Pharmacol. 2020;86(5):852–860.
   PubMed Web of Science ®Google Scholar
• Alemayehu B, Speiser J, Bloudek L, et al. Costs associated with long-acting insulin analogues in patients with diabetes. Am J Manag Care. 2018;24(8 Spec No):Sp265–sp72.
   PubMed Web of Science ®Google Scholar
• Gordon J, Evans M, McEwan P, et al. Evaluation of insulin use and value for money in type 2 diabetes in the United kingdom. Diabetes Ther. 2013;4(1):51–66.
   PubMed Web of Science ®Google Scholar
• Gururaj Setty S, Crasto W, Jarvis J, et al. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J. 2016;92(1085):152–164.
   PubMed Web of Science ®Google Scholar
• Godman B. Biosimilars are becoming indispensable in the management of multiple diseases although concerns still exist. Bangladesh J Med Sci. 2021;20(1):5–10.
   Web of Science ®Google Scholar
• Godman B, Allocati E, Moorkens E, et al. Can local policies on biosimilars optimize the use of freed resources – experiences from Italy. GaBI J. ). 2020; 9(4):183–187.
   Google Scholar
• Matusewicz W, Godman B, Pedersen HB, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–758.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Misery L, Naeyaert S, et al. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279.
   PubMed Web of Science ®Google Scholar
• Jensen TB, Kim SC, Jimenez-Solem E, et al. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902–903.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kwon H-Y, Godman B, et al. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol. 2020;11:970.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Godman B, Huys I, et al. The expiry of Humira market exclusivity and the entry of adalimumab biosimilars in Europe: An overview of pricing and national policy measures. Front Pharmacol. 2020;11(1993):591134.
   PubMed Web of Science ®Google Scholar
• Taki K, Koyanagi M, Nagaoka S, et al. Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study. Curr Med Res Opin. 2020;36(12):1975–1983.
   PubMed Web of Science ®Google Scholar
• Blevins TC, Barve A, Raiter Y, et al. Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: results of the INSTRIDE 3 phase 3 switch study. Diabetes Obes Metab. 2020;22(3):365–372.
   PubMed Web of Science ®Google Scholar
• Lamb YN, Syed YY. LY2963016 insulin glargine: a review in type 1 and 2 diabetes. BioDrugs. 2018;32(1):91–98.
   PubMed Web of Science ®Google Scholar
• Hadjiyianni I, Dahl D, Lacaya LB, et al. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obes Metab. 2016;18(4):425–429.
   PubMed Web of Science ®Google Scholar
• Hoy SM. MYL1501D insulin glargine: a review in diabetes mellitus. BioDrugs. 2020;34(2):245–251.
   PubMed Web of Science ®Google Scholar
• Greater Glasgow and Clyde. Medicines Update - Semglee – preferred brand of insulin glargine. 2020. Available at URL: http://ggcprescribing.org.uk/blog/alternatives-insulin-glargine-post-tc/.
   Google Scholar
• Greener M. Why isn’t the NHS making the most of biosimilar insulin? Prescriber. 2019;30(8):21–24.
   Google Scholar
• Aladul MI, Fitzpatrick RW, Chapman SR. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study. BMJ Open. 2018;8(11):e023603.
   PubMed Web of Science ®Google Scholar
• Godman B, Haque M, Leong T, et al. The current situation regarding long-acting insulin analogues including biosimilars among selected African, Asian, European and South American countries: findings and implications for the future. Frontiers in Public Health. 2021. DOI:10.3389/fpubh.2021.671961
   PubMed Web of Science ®Google Scholar
• Bertolani A, Jommi C. Local policies on biosimilars: are they designed to optimize use of liberated resources? GaBI J. 2020; 9(4):163–170.
   Google Scholar
• Godman B, Allocati E, Moorkens E. Ever-Evolving landscape of biosimilars in Canada; findings and implications from a global perspective. GaBI J. 2019;8(3):93–97.
   Google Scholar
• Khan JAM, Ahmed S, Evans TG. Catastrophic healthcare expenditure and poverty related to out-of-pocket payments for healthcare in Bangladesh-an estimation of financial risk protection of universal health coverage. Health Policy Plan. 2017;32(8):1102–1110.
   PubMed Web of Science ®Google Scholar
• Murphy A, Palafox B, Walli-Attaei M, et al. The household economic burden of non-communicable diseases in 18 countries. BMJ Glob Health. 2020;5(2):e002040.
   PubMed Web of Science ®Google Scholar
• Kastor A, Mohanty SK. Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: do Indian households face distress health financing? PloS One. 2018;13(5):e0196106.
   PubMed Web of Science ®Google Scholar
• Datta BK, Husain MJ, Asma S. Assessing the relationship between out-of-pocket spending on blood pressure and diabetes medication and household catastrophic health expenditure: evidence from Pakistan. Int J Equity Health. 2019;18(1):9.
   PubMed Web of Science ®Google Scholar
• Haque M, Islam S, Abubakar AR, et al. Utilisation and expenditure on long-acting insulin analogues among selected middle-income countries with high patient co-payment levels: findings and implications for the future. J Appl Pharm Sci. 2021 (in press).
   Google Scholar
• Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res. 2012;1(6):527–538.
   PubMed Web of Science ®Google Scholar
• Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):469–482.
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65–83.
   PubMedGoogle Scholar
• Dylst P, Simoens S. Does the market share of generic medicines influence the price level?: a European analysis. Pharmacoeconomics. 2011;29(10):875–882.
   PubMed Web of Science ®Google Scholar
• Gotham D, Barber MJ, Hill A. Production costs and potential prices for biosimilars of human insulin and insulin analogues. BMJ Glob Health. 2018;3(5):e000850.
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Sugahara T, Timofeyev Y, et al. Predictors of (in)efficiencies of Healthcare Expenditure Among the Leading Asian Economies - Comparison of OECD and Non-OECD Nations. Risk Manag Healthc Policy. 2020;13:2261–2280.
   PubMed Web of Science ®Google Scholar
• Godman B, Haque M, Islam S, et al. Rapid assessment of price instability and paucity of medicines and protection for COVID-19 across Asia: findings and public health implications for the future. Front Public Health. 2020;8:585832.
   PubMed Web of Science ®Google Scholar
• Haque M, Kumar S, Charan J, et al. Utilisation, availability and price changes of medicines and protection equipment for COVID-19 in India: findings and implications Short title: COVID-19 and price changes of treatments in India. Front Pharmacol. 2021;11:582154.
   Web of Science ®Google Scholar
• Haque M, Islam S, Iqbal S, et al. Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. Bangladesh J Med Sci. 2020; 19 (Special Issue on Covid19):S36–S50.
   Google Scholar
• Singh S. Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification. 2019. Available at URL: https://indiamedtoday.com/biocons-malaysia-insulin-glargine-manufacturing-facility-receives-eu-gmp-certification/.
   Google Scholar
• World Bank. GDP per Capita. 2020. Available at URL: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
   Google Scholar
• OECD. Countries Of The World. 2021. Available at URL: https://www.worldatlas.com/countries.
   Google Scholar
• Sefah I, Ogunleye O, Essah D, et al. Rapid assessment of the potential paucity and price increases for suggested medicines and protection equipment for COVID-19 across developing countries with a particular focus on Africa and the implications. Front Pharmacol. 2021;11:588106.
   Web of Science ®Google Scholar
• Haque M, Islam S, Kamal ZM, et al. Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications. Hospital Pract. 2021. DOI:10.1080/21548331.2021.1906083
   Google Scholar
• Shakeri A, Srimurugathasan N, Suda KJ, et al. Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. Value Health. 2020;23(9):1137–1141.
   PubMed Web of Science ®Google Scholar
• Xu Y, Gomes T, Mamdani MM, et al. Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015. Can J Diabetes. 2019;43(3):179–185.e1.
   PubMed Web of Science ®Google Scholar
• Langner JL, Chiang KF, Stafford RS. Current prescribing practices and guideline concordance for the treatment of uncomplicated urinary tract infections in women. Am J Obstet Gynecol. 2021. DOI:10.1016/j.ajog.2021.04.218
   PubMed Web of Science ®Google Scholar
• Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018;115(15):E3463–e70.
   PubMed Web of Science ®Google Scholar
• Godman B, McCabe H, Leong T, et al. Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev Pharmacoecon Outcomes Res. 2020;20(1):1–26.
   PubMed Web of Science ®Google Scholar
• Godman B, Haque M, McKimm J, et al. Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. Curr Med Res Opin. 2020;36(2):301–327.
   PubMed Web of Science ®Google Scholar
• Gad M, Salem A, Oortwijn W, et al. Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions. Front Pharmacol. 2020; 11:144.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: An overview. PLoS One. 2017;12(12):e0190147.
   PubMed Web of Science ®Google Scholar
• Godman B, Hill A, Simoens S, et al. Pricing of oral generic cancer medicines in 25 European countries; findings and implications. GaBI J. 2019;8(2):49–70.
   Google Scholar
• Miljković N, Godman B, van Overbeeke E, et al. Risks in antibiotic substitution following medicine shortage: a health-care failure mode and effect analysis of six European hospitals. Front Med. 2020;7:157.
   Web of Science ®Google Scholar
• Mwita JC, Ogunleye OO, Olalekan A, Kalungia AC, et al. Key issues surrounding appropriate antibiotic use for prevention of surgical site infections in low- and middle-income countries: a narrative review and the implications. Int J Gen Med. 2021;14:515–530.
   PubMed Web of Science ®Google Scholar
• Miljković N, Godman B, Kovačević M, et al. Prospective risk assessment of medicine shortages in Europe and Israel: findings and implications. Front Pharmacol. 2020; 11:357.
   PubMed Web of Science ®Google Scholar
• Rahman MM, Zhang C, Swe KT, et al. Disease-specific out-of-pocket healthcare expenditure in urban Bangladesh: A Bayesian analysis. PLoS One. 2020;15(1):e0227565.
   PubMed Web of Science ®Google Scholar
• Mashalla Y, Setlhare V, Massele A, et al. Assessment of prescribing practices at the primary healthcare facilities in Botswana with an emphasis on antibiotics: Findings and implications. Int J Clin Pract. 2017;71(12):e13042.
   Web of Science ®Google Scholar
• Mwita JC, Godman B, Esterhuizen TM. Statin prescription among patients with type 2 diabetes in Botswana: findings and implications. BMC Endocr Disord. 2020;20(1):36.
   PubMed Web of Science ®Google Scholar
• Mwita JC, Francis JM, Omech B, et al. Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study. BMJ Open. 2019;9(7):e026807.
   PubMed Web of Science ®Google Scholar
• Rwegerera GM, Masaka A, Pina-Rivera Y, et al. Determinants of glycemic control among diabetes mellitus patients in a tertiary clinic in Gaborone, Botswana: findings and implications. Hospital Practice (1995). 2019;47(1):34–41.
   PubMedGoogle Scholar
• Ministry of Health Republic of Ghana. Ghana National Drugs Programme (GNDP) - Essential Medicines List. 7th Edition. 2017. Available at URL https://www.moh.gov.gh/wp-content/uploads/2020/07/GHANA-EML-2017.pdf.
   Google Scholar
• Sood N, Wagner Z. JAMA Health Forum. India’s Historic Effort to Expand Health Insurance to Individuals Living Below the Poverty Line. 2020. Available at URL: https://jamanetwork.com/channels/health-forum/fullarticle/2763530.
   Google Scholar
• Reddy KS. Health Care Reforms in India. Jama. 2018;319(24):2477–2478.
   PubMed Web of Science ®Google Scholar
• Branch P. After Faltering Start, Japan’s Biosimilars Market Appears on Cusp of Rapid Growth. 2020. Available at URL: https://www.lek.com/sites/default/files/PDFs/LEK_Japan-Biosimilars.pdf.
   Google Scholar
• Global Data. Global rheumatologists’ biosimilar prescription rates shift from 2018. to 2020. 2021. Available at URL: https://www.pharmaceutical-technology.com/comment/rheumatologist-biosimilar-prescription-rates/.
   Google Scholar
• Shannon GD, Haghparast-Bidgoli H, Chelagat W, et al. Innovating to increase access to diabetes care in Kenya: an evaluation of Novo Nordisk's base of the pyramid project. Glob Health Action. 2019;12(1):1605704.
   PubMed Web of Science ®Google Scholar
• Sandoz - A Novartis Division. Kenya is first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases. 2015. Available at URL: https://www.sandoz.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment.
   Google Scholar
• Ministry of Health Republic of Kenya. Kenya Essential medicines list - 2019. Availabe at URL: https://www.health.go.ke/wp-content/uploads/2020/03/Kenya-Essential-Medicines-List-2019.pdf.
   Google Scholar
• Kwon H-Y, Kim H, Godman B. Availability and affordability of drugs with a conditional approval by the European medicines agency; comparison of Korea with other countries and the implications. Front Pharmacol. 2018;9(:938.
   PubMed Web of Science ®Google Scholar
• Kwon HY, Godman B. Drug pricing in South Korea. Appl Health Econ Health Policy. 2017;15(4):447–453.
   PubMed Web of Science ®Google Scholar
• Rezal RS, Hassali MA, Alrasheedy AA, et al. Prescribing patterns for upper respiratory tract infections: a prescription-review of primary care practice in Kedah, Malaysia, and the implications. Expert Rev anti Infect Ther. 2015;13(12):1547–1556.
   PubMed Web of Science ®Google Scholar
• Aregbeshola BS, Khan SM. Out-of-pocket payments, catastrophic health expenditure and poverty among households in Nigeria 2010. Int J Health Policy Manag. 2018;7(9):798–806.
   PubMed Web of Science ®Google Scholar
• Haque M, Abubakar A, Ogunleye O, et al. Changes in availability, utilization, and prices of medicines and protection equipment for COVID-19 in an Urban population of Northern Nigeria. J Res Pharm Pract. 2021;10(1):17–22.
   PubMed Web of Science ®Google Scholar
• Fadare J, Olamoyegun M, Gbadegesin BA. Medication adherence and direct treatment cost among diabetes patients attending a tertiary healthcare facility in Ogbomosho, Nigeria. Malawi Med J. 2015;27(2):65–70.
   PubMed Web of Science ®Google Scholar
• Mutyambizi C, Pavlova M, Chola L, et al. Cost of diabetes mellitus in Africa: a systematic review of existing literature. Global Health. 2018;14(1):3.
   PubMed Web of Science ®Google Scholar
• Meyer JC, Schellack N, Stokes J, et al. Ongoing initiatives to improve the quality and efficiency of medicine use within the public healthcare system in South Africa; a preliminary study. Front Pharmacol. 2017;8:751.
   PubMed Web of Science ®Google Scholar
• Moosa A, Bezuidenhout S, Meyer JC, et al. Knowledge regarding medicines management of type-2 diabetes among patients attending a Community Health Centre in South Africa. J Pharmaceu Health Serv Res. 2019;10(1):13–21.
   Google Scholar
• Afroz A, Zhang W, Wei Loh AJ, et al. Macro- and micro-vascular complications and their determinants among people with type 2 diabetes in Bangladesh. Diabetes Metab Syndr. 2019;13(5):2939–2946.
   PubMed Web of Science ®Google Scholar
• Shariful Islam SM, Lechner A, Ferrari U, et al. Healthcare use and expenditure for diabetes in Bangladesh. BMJ Glob Health. 2017;2(1):e000033-e.
   Web of Science ®Google Scholar
• India State-Level Disease Burden Initiative Diabetes C. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016. The Lancet Global Health. 2018;6(12):e1352–e62.
   PubMed Web of Science ®Google Scholar
• Vijayakumar G, Manghat S, Vijayakumar R, et al. Incidence of type 2 diabetes mellitus and prediabetes in Kerala, India: results from a 10-year prospective cohort. BMC Public Health. 2019;19(1):140.
   PubMed Web of Science ®Google Scholar
• Ikeda N, Nishi N, Noda H, et al. Trends in prevalence and management of diabetes and related vascular risks in Japanese adults: Japan National Health and Nutrition Surveys 2003–2012. Diabetes Res Clin Pract. 2017;127:115–122.
   PubMed Web of Science ®Google Scholar
• Mukai N, Hata J, Hirakawa Y, et al. Trends in the prevalence of type 2 diabetes and prediabetes in a Japanese community, 1988-2012: the Hisayama Study. Diabetol Int. 2019;10(3):198–205.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Ninth Edition - Country Summary Table. 2019. Available at URL: https://diabetesatlas.org/en/resources/.
   Google Scholar
• Goto A, Noda M, Inoue M, et al. Increasing number of people with diabetes in Japan: is this trend real? Intern Med. 2016;55(14):1827–1830.
   PubMed Web of Science ®Google Scholar
• Shin JY. Trends in the prevalence and management of diabetes in Korea: 2007-2017. Epidemiol Health. 2019;41:e2019029.
   PubMed Web of Science ®Google Scholar
• Ko SH, TaskForce Team for the Diabetes Fact Sheet of the Korean Diabetes Association, Han K, Lee YH, Noh J, Park CY, Kim DJ, et al. Past and current status of adult type 2 diabetes mellitus management in Korea: a national health insurance service database analysis. Diabetes Metab J. 2018;42(2):93–100.
   PubMed Web of Science ®Google Scholar
• Jung CH. Comprehensive efforts are needed to improve the quality of primary diabetes care in Korea. Endocrinol Metab (Seoul)). 2019;34(3):265–267.
   PubMedGoogle Scholar
• Rahim FF, Abdulrahman SA, Kader Maideen SF, et al. Prevalence and factors associated with prediabetes and diabetes in fishing communities in Penang, Malaysia: A cross-sectional study. PLoS One. 2020;15(2):e0228570.
   PubMed Web of Science ®Google Scholar
• Ayub I. Pakistan among top 10 countries in prevalence of diabetes. 2019. Available at URL: https://www.dawn.com/news/1516581.
   Google Scholar
• Davio K. After Biosimilar Deals, UK Spending on Adalimumab Will Drop by 75%. 2018. Available at URL: https://www.centerforbiosimilars.com/news/after-biosimilar-deals-uk-spending-on-adalimumab-will-drop-by-75.
   Google Scholar
• Hara F, Tajima K, Tanabe K. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer. Future Oncol. 2019;15(12):1353–1361.
   PubMed Web of Science ®Google Scholar
• London Procurement Partnership. Uptake of Biosimilar Etanercept, Rituximab, Trastuzumab and Adalimumab in London (Feb 2019. Available at URL: http://www.lpp.nhs.uk/categories/medicines-optimisation-pharmacy-procurement/secondary-care/biosimilars/.
   Google Scholar
• Kuribayashi R, Sawanobori K. Current Japanese regulatory systems for generics and biosimilars. J Pharm Sci. 2018;107(3):785–787.
   PubMed Web of Science ®Google Scholar
• Kim M, Monnard A, da Silva JS. Despite a sluggish start, Japan’s biosimilar market looks set for accelerated growth. The country’s patient co-pay dynamic, financial incentives, and commercial model will be keys to success. 2019. Available at URL. https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/understanding-the-opportunity-in-japans-biosimilar-market.
   Google Scholar
• Arato T. Japanese regulation of biosimilar products: past experience and current challenges. Br J Clin Pharmacol. 2016;82(1):30–40.
   PubMed Web of Science ®Google Scholar
• Research And Markets. The Biosimilars Landscape in Japan 2020. 2020. Available at URL: https://www.businesswire.com/news/home/20201020005765/en/The-Biosimilars-Landscape-in-Japan-2020–-ResearchAndMarkets.com.
   Google Scholar
• Horikawa H, Tsubouchi M, Kawakami K. Industry views of biosimilar development in Japan. Health Policy. 2009;91(2):189–194.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kobayashi T, Nishikawa K, et al. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res. 2019;17(4):504–515.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Tsuchiya T, Hirano T, et al. Changes in the penetration rate of biosimilar infliximab within Japan using a Japanese claims database. Clinicoecon Outcomes Res. 2021;13:145–153.
   PubMed Web of Science ®Google Scholar
• HIRA. Updates of the NHIS drug list for reimbursement 2020. Available at URL: http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000.
   Google Scholar
• Lee HJ, Han E, Kim H. Comparison of utilization trends between biosimilars and generics: lessons from the nationwide claims data in South Korea. Appl Health Econ Health Policy. 2020;18(4):557–566.
   PubMed Web of Science ®Google Scholar
• Biocon. Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia. 2017. Available at URL: https://www.biocon.com/biocon-wins-myr-300-million-contract-for-insulin-from-moh-malaysia/.
   Google Scholar
• GABI Online. Biocon wins three-year contract to supply insulin in Malaysia. 2017. Available at URL: http://www.gabionline.net/Biosimilars/News/Biocon-wins-three-year-contract-to-supply-insulin-in-Malaysia.
   Google Scholar
• Government of Malaysia. MALAYSIA’S GOVERNMENT PROCUREMENT REGIME. 2010. Available at URL: https://www.treasury.gov.my/pdf/lain-lain/msia_regime.pdf.
   Google Scholar
• Khan B, Godman B, Babar A, et al. Assessment of active pharmaceutical ingredients in drug registration procedures in Pakistan: implications for the future. GaBI J. ). 2016;5(4):156–163.
   Google Scholar
• Rasheed H, Hoellein L, Bukhari KS, et al. Regulatory framework in Pakistan: situation analysis of medicine quality and future recommendations. J Pharm Policy Pract. 2019;12:23.
   PubMedGoogle Scholar
• Addressing Asia's fast growing diabetes epidemic. Bull World Health Organ. 2017;95(8):550–551.
   PubMed Web of Science ®Google Scholar
• Fiotec. Technology transfer by Ukrainian company for Recombinant Human Insulin production in Farmanguinhos. 2015. Available at URL: https://www.fiotec.fiocruz.br/en/news/2791-technology-transfer-by-ukrainian-company-for-recombinant-human-insulin-production-in-farmanguinhos.
   Google Scholar
• Ogunleye OO, Basu D, Mueller D, et al. Response to the novel corona virus (COVID-19) pandemic across Africa: successes, challenges, and implications for the future. Front Pharmacol. 2020;11:1205.
   Web of Science ®Google Scholar
• EAC Secretariat. East African Community COVID-19 Response Plan. 2020. Available at URL: https://www.eac.int/coronavirus.
   Google Scholar
• Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. Front Pharmacol. 2019;10(:1372.
   PubMed Web of Science ®Google Scholar
• Research and Markets. $24 Billion Insulin Markets - Global Intelligence Database 2012–2018 & 2019–2023. 2019. Available at URL: https://www.globenewswire.com/news-release/2019/05/29/1856512/0/en/24-Billion-Insulin-Markets-Global-Intelligence-Database-2012-2018-2019-2023.html.
   Google Scholar
• La Merie Publishing. 2019. Sales of Recombinant Therapeutic Antibodies & Proteins. 2020. Available at URL: https://lamerie.com/report/blockbuster-biologics-2019-sales-of-recombinant-therapeutic-antibodies-proteins/.
   Google Scholar
• Resarch and Markets. Asia-Pacific's $786M Biosimilar Insulin Glargine & Lispro Market, 2024. 2020. Available at URL: https://www.prnewswire.com/news-releases/asia-pacifics-786m-biosimilar-insulin-glargine–lispro-market-2024-301002002.html.
   Google Scholar
• NHS Scotland. Secondary Care National Therapeutic Indicators 2019/20. 2019. Avai;able at URL: https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2020/10/Secondary-care-NTIs-2019-20-final.pdf.
   Google Scholar
• Campbell SM, Godman B, Diogene E, et al. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin Pharmacol Toxicol. 2015;116(2):146–157.
   PubMed Web of Science ®Google Scholar
• Campbell SM, Kontopantelis E, Hannon K, et al. Framework and indicator testing protocol for developing and piloting quality indicators for the UK quality and outcomes framework. BMC Fam Pract. 2011;12:85.
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Neovius M, et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy. 2010;94(3):221–229.
   PubMed Web of Science ®Google Scholar
• Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11(1):121–129.
   PubMed Web of Science ®Google Scholar
• Fürst J, Čižman M, Mrak J, et al. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. Expert Rev anti Infect Ther. 2015;13(2):279–289.
   PubMed Web of Science ®Google Scholar
• Leporowski A, Godman B, Kurdi A, et al. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Rev Pharmacoecon Outcomes Res. 2018;18(6):655–666.
   PubMed Web of Science ®Google Scholar
• Hesse U, Godman B, Petzold M, et al. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. Appl Health Econ Health Policy. 2013;11(6):677–685.
   PubMedGoogle Scholar
• Jakovljevic M, Potapchik E, Popovich L, et al. Evolving health expenditure landscape of the BRICS nations and projections to 2025. Health Econ. 2017;26(7):844–852.
   PubMed Web of Science ®Google Scholar
• Jakovljevic MM. Comparison of historical medical spending patterns among the BRICS and G7. J Med Econ. 2016;19(1):70–76.
   PubMed Web of Science ®Google Scholar
• Rancic N, Jakovljevic MM. Long term health spending alongside population aging in N-11 emerging nations. Eastern European Business and Economics Journal. 2016; 2(1):2–26.
   Google Scholar
• Jakovljevic M, Timofeyev Y, Ekkert NV, et al. The impact of health expenditures on public health in BRICS nations. J Sport Health Sci. 2019;8(6):516–519.
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Getzen TE. Growth of global health spending share in low and middle income countries. Front Pharmacol. 2016;7(:21.
   PubMed Web of Science ®Google Scholar
• WHO. WHO launches first-ever insulin prequalification programme to expand access to life-saving treatment for diabetes. 2019. Available at URL: https://www.who.int/news/item/13-11-2019-who-launches-first-ever-insulin-prequalification-programme-to-expand-access-to-life-saving-treatment-for-diabetes.
   Google Scholar
• Beran D, Lazo-Porras M, Mba CM, et al. A global perspective on the issue of access to insulin. Diabetologia. 2021;64(5):954–962.
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Timofeyev Y, Ranabhat CL, et al. Real GDP growth rates and healthcare spending - comparison between the G7 and the EM7 countries. Global Health. 2020;16(1):64.
   PubMed Web of Science ®Google Scholar